Literature DB >> 9591211

Stromal IGF-II messenger RNA in breast cancer: relationship with progesterone receptor expressed by malignant epithelial cells.

C Giani1, A Pinchera, A Rasmussen, P Fierabracci, R Bonacci, D Campini, G Bevilacqua, B Trock, M E Lippman, K J Cullen.   

Abstract

In breast cancer, insulin-like growth factor II (IGF-II) is stromal in origin and is considered an important regulator of tumour epithelium growth. The presence of progesterone receptor (PR) is expression of an intact oestrogen regulatory pathway of breast malignant epithelial cells and represents a parameter of cell differentiation in breast cancer. In this study we have examined the relationship between IGF-II mRNA expression and ER, PR content in 75 breast cancer. Formalin-fixed paraffin-embedded tissue sections were used to preserve histological details. IGF-II mRNA was evaluated by in situ hybridisation method and ER, PR by immunohistochemistry. IGF-II mRNA was scored semi-quantitatively: 2.6% breast tumour specimen expressed no IGF-II mRNA, 46.7% had low levels of expression (IGF-II-) and 50.7% had moderate or high IGF-II mRNA content (IGF-II+). IGF-II mRNA was found in the stroma fibroblasts surrounding malignant lesions and no signal was detected in malignant epithelial cells. In contrast, ER and PR were expressed only by neoplastic epithelial cells and no immunoreactivity was found in the stroma: 50/75 (66.6%) breast cancer specimens were positive for ER (ER+) and 35 (46.6%) for PR (PR+). Both, IGF-II mRNA and PR were directly correlated with the stromal proliferation (p < 0.05 and p < 0.001, respectively). No relationship was found between IGF-II RNA and ER. In contrast 24/35 (73.5%) PR breast cancer tissues were IGF-II+ (p < 0.01) and a strong correlation was found between epithelial PR immunostaining and stromal IGF-II mRNA content (p < 0.003). Our data indicate that in breast cancer IGF-II mRNA is generally expressed by stromal cells and ER and PR by epithelial cancer cells, and that IGF-II mRNA expression is strongly related with both percentage and staining intensity of PR+ epithelial cancer cells. These data support the hypothesis that IGF-II produced by the fibroblasts may exert a paracrin effect on malignant epithelium regulating its differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591211     DOI: 10.1007/BF03347295

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Hormonal regulation of human growth.

Authors:  M M Rechler; S P Nissley; J Roth
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

2.  Mesenchyme-mediated effect of testosterone on embryonic mammary epithelium.

Authors:  H Dürnberger; B Heuberger; P Schwartz; G Wasner; K Kratochwil
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

3.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

Review 4.  Growth regulation of human breast carcinoma occurs through regulated growth factor secretion.

Authors:  M E Lippman; R B Dickson; E P Gelmann; N Rosen; C Knabbe; S Bates; D Bronzert; K Huff; A Kasid
Journal:  J Cell Biochem       Date:  1987-09       Impact factor: 4.429

5.  Growth abnormalities of cultured human skin fibroblasts derived from individuals with hereditary adenomatosis of the colon and rectum.

Authors:  L Pfeffer; M Lipkin; O Stutman; L Kopelovich
Journal:  J Cell Physiol       Date:  1976-09       Impact factor: 6.384

Review 6.  Insulin-like growth factor expression in breast cancer epithelium and stroma.

Authors:  K J Cullen; A Allison; I Martire; M Ellis; C Singer
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Mammary stroma modulates hormonal responsiveness of mammary epithelium in vivo in the mouse.

Authors:  S Z Haslam; L J Counterman
Journal:  Endocrinology       Date:  1991-10       Impact factor: 4.736

8.  Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts.

Authors:  A M Grey; A M Schor; G Rushton; I Ellis; S L Schor
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Skin fibroblasts obtained from cancer patients display foetal-like migratory behaviour on collagen gels.

Authors:  S L Schor; A M Schor; P Durning; G Rushton
Journal:  J Cell Sci       Date:  1985-02       Impact factor: 5.285

10.  Relationship between progesterone receptor and productive fibrosis as an index of tumor differentiation in breast cancer.

Authors:  C Giani; A Pinchera; M Breccia; D Campani; F De Negri; G Benigni; G Evangelista; P Miccoli; M R Savarese; R Incensati
Journal:  Tumori       Date:  1988-06-30
View more
  8 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

2.  Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.

Authors:  K Abdul-Wahab; D Corcoran; A Perachiotti; P D Darbre
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

3.  Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways.

Authors:  Eileen Hsu; Carol A Feghali-Bostwick
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

Review 4.  Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer.

Authors:  X Zhang; D Yee
Journal:  Breast Cancer Res       Date:  2000-03-06       Impact factor: 6.466

5.  Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture.

Authors:  Andrea Sadlonova; Zdenek Novak; Martin R Johnson; Damon B Bowe; Sandra R Gault; Grier P Page; Jaideep V Thottassery; Danny R Welch; Andra R Frost
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

Review 6.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.

Authors:  Zhizhen Chen; Jie Liu; Dafeng Chu; Yaming Shan; Guixing Ma; Hongmin Zhang; Xiaohua Douglas Zhang; Pu Wang; Qiang Chen; Chuxia Deng; Weizao Chen; Dimiter S Dimitrov; Qi Zhao
Journal:  Int J Biol Sci       Date:  2018-05-21       Impact factor: 6.580

8.  A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.

Authors:  Rosalyne L Westley; Felicity E B May
Journal:  Int J Endocrinol       Date:  2013-07-31       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.